Chemotherapy of canine leishmaniosis

Veterinary Parasitology

Volumn 106, Issue 4, 2002, Pages 315-324

  Baneth, Gad ^a   Shaw, Susan E ^b  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

Allopurinol; Aminosidine; Amphotericin B; Dog; Leishmania infantum; Meglumine antimoniate; Pentamidine

Indexed keywords

ALLOPURINOL; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANTIMONY DERIVATIVE; BUPARVAQUONE; FLUCONAZOLE; INTRALIPID; ITRACONAZOLE; KETOCONAZOLE; MEGLUMINE ANTIMONATE; METRONIDAZOLE; MILTEFOSINE; PAROMOMYCIN; PENTAMIDINE MESYLATE; TERBINAFINE;

ANTIBODY TITER; ARTICLE; CHEMOTHERAPY; COST EFFECTIVENESS ANALYSIS; DOG DISEASE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG COST; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FATALITY; IMMUNE RESPONSE; IMMUNOLOGICAL PARAMETERS; INFECTION PREVENTION; LEISHMANIA INFANTUM; LEISHMANIASIS; NONHUMAN; PARASITE CONTROL; RELAPSE; REMISSION;

ANIMALS; ANTIPROTOZOAL AGENTS; DOG DISEASES; DOGS; LEISHMANIASIS, VISCERAL;

CANIS FAMILIARIS; LEISHMANIA INFANTUM;

EID: 0037007944     PISSN: 03044017     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-4017(02)00115-2     Document Type: Article

References (40)

1. Canine leishmaniosis: Clinical, parasitological and entomological follow-up after chemotherapy
2. Allopurinol treatment diminishes the infectivity of dogs with canine leishmaniosis to Lutzomyia longipalpis sand flies
3. Disposition of antimony and aminosidine combination after multiple subcutaneous injections
4. Clinical, serologic, and parasitologic follow-up after long term allopurinol therapy of dogs naturally infected with Leishmania infantum
5. Treatment of visceral leishmaniosis in Kenya by aminosidine alone or combined with sodium stibogluconate
6. Combination allopurinol and antimony treatment versus antimony alone and allopurinol alone in the treatment of canine leishmaniosis (96 cases)
7. Parasitological and immunological follow-up examinations during and after chemotherapy of leishmaniosis in dogs
8. Experimental evaluation of second-line oral treatments of visceral leishmaniosis caused by Leishmania infantum
9. Use of allopurinol for maintenance of remission in dogs with leishmaniosis
10. Decreased sensitivity to meglumine antimoniate (Glucantime) of Leishmania infantum isolated from dogs after several courses of drug treatment
11. Clinical considerations on canine visceral leishmaniosis in Greece: A retrospective study of 158 cases (1989-1996)
12. A randomized, blinded, placebo-controlled clinical trial with allopurinol in canine leishmaniosis
13. Hexadecylphosphocholine: Oral treatment of visceral leishmaniosis in mice
14. Essai de traitement de la leishmaniose canine par l'amphotericine B: 39 cas
15. Activity of amphotericin B in lipid emulsion in the initial treatment of canine leishmaniosis
16. Xanthine-containing urinary calculi in dogs given allopurinol
17. Combination chemotherapy of canine and feline cryptococcosis using subcutaneously administered amphotericin
18. Old world leishmaniosis
19. The synergistic action of pyrazolopyrimidines and pentavalent antimony against Leishmania donovani and L. braziliensis
20. The immune response and PBMC subsets in canine visceral leishmaniosis before, and after chemotherapy
21. Clinical follow-up examination after treatment of canine leishmaniosis
22. Visceral leishmanicidal activity of hexadecylphosphocholine (Miltefosine) in mice deficient in T cells and activated macrophage microbiocidal mechanisms
23. Activity of liposomal amphotericin B (AmBisome) in dogs naturally infected with Leishmania infantum
24. Comparison of aminosidine (paromomycin) and sodium stibogluconate for treatment of canine leishmaniosis
25. Analysis of immune responses in dogs with canine visceral leishmaniosis before, and after, drug treatment
26. Serological and parasitological follow-up in dogs experimentally infected with Leishmania infantum and treated with meglumine antimoniate
27. Aminosidine (paromomycin) in the treatment of leishmaniosis imported into the United Kingdom
28. ®) in dogs with leishmaniosis
29. A review of canine leishmaniosis presenting outside endemic areas
30. Oral treatment with miltefosine for visceral leishmaniosis
31. Pharmacokinetics of N-methylglucamine antimoniate after intravenous, intramuscular and subcutaneous administration in the dog
32. Disposition of antimony after the administration of N-methylglucamine antimoniate to dogs
33. Pharmacokinetics of liposome-encapsulated meglumine antimoniate after intramuscular and subcutaneous administration in dogs
34. Pharmacokimetics of meglumine antimoniate after administration of a multiple dose in dogs experimentally infected with Leishmania infantum
35. Long term improvement in the treatment of canine leishmaniosis using an antimony liposomal formulation
36. First evaluation of the use of allopurinol as a single drug for the treatment of canine leishmaniosis
37. Clinical recovery and limited cure in canine visceral leishmaniosis treated with aminosidine (paromomycin)
38. Failure of buparvaquone (Butalex) in the treatment of canine visceral leishmaniosis
39. Canine visceral leishmaniosis: Successful chemotherapy induces macrophage antileishmanial activity via the L-arginine nitric oxide pathway
40. Amphotericin B in lipid emulsion: Stability, compatibility, and in vitro antifungal activity